NCT03481010

Brief Summary

At present, it is not clear whether performing a hip arthroscopy at the same time as a PAO improves patient outcomes after surgery compared to a PAO alone. This research project will randomize patients to receive either a PAO alone, or a PAO and a hip arthroscopy at the same time.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
204

participants targeted

Target at P75+ for not_applicable

Timeline
56mo left

Started Apr 2018

Longer than P75 for not_applicable

Geographic Reach
2 countries

7 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress64%
Apr 2018Dec 2030

First Submitted

Initial submission to the registry

March 15, 2018

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 29, 2018

Completed
6 days until next milestone

Study Start

First participant enrolled

April 4, 2018

Completed
12.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2030

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2030

Last Updated

December 30, 2025

Status Verified

December 1, 2025

Enrollment Period

12.3 years

First QC Date

March 15, 2018

Last Update Submit

December 24, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • iHOT-33

    Patient-reported quality of life will be the primary outcome used for comparison between the two treatment groups as measured by the International Hip Outcome Tool (iHOT-33). The iHOT-33 is a validated, self-administered quality of life assessment tool for young, active patients with hip symptoms.

    24 months

Secondary Outcomes (6)

  • HOOS

    before surgery, 6 months, 12 months, 24 months after surgery

  • PROMIS Global 10

    before surgery, 6 months, 12 months, 24 months after surgery

  • Operative time

    intra-operative

  • Hospital Length of Stay

    up to one month

  • Adverse Events

    2-4 weeks and 3 months after surgery

  • +1 more secondary outcomes

Study Arms (2)

PAO with hip arthroscopy

EXPERIMENTAL

Patient's in the "Scope PAO" group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the "Scope-PAO" group have been randomized to receive a periacetabular osteotomy with a hip arthroscopy.

Procedure: PAO with hip arthroscopy

PAO without hip arthroscopy

ACTIVE COMPARATOR

Patient's in the "PAO-only" group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the "PAO-only" group have been randomized to receive a periacetabular osteotomy only.

Procedure: PAO without hip arthroscopy

Interventions

Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.

PAO with hip arthroscopy

Participants who are randomized to the "PAO-only" group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia.

PAO without hip arthroscopy

Eligibility Criteria

Age16 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Skeletally mature patient undergoing Bernese periacetabular osteotomy for symptomatic acetabular dysplasia/hip instability
  • Pre-Operative MRI at 3T and/or gadolinium MR arthrogram
  • Age, 16-50 years old
  • Patient capable of giving informed consent

You may not qualify if:

  • Prior hip/pelvis surgery of any kind on the surgical side
  • Prior hip arthroplasty surgery on either side
  • Radiographic evidence of arthritis (i.e. Tönnis grade =2)
  • Known connective tissue disorder (e.g. Ehlers-Danlos Syndrome, etc.)
  • Known neuromuscular disorder (e.g. Cerebral Palsy, Spina bifida, etc.)
  • Known skeletal dysplasia (e.g. Achondroplasia, Multiple Epiphyseal Dysplasia, etc.)
  • Cognitive impairment that prevents accurate completion of patient-reported outcome questionnaires.
  • Patient unable/unwilling to complete all required follow-up visits
  • Concurrent proximal femoral osteotomy and/or surgical hip dislocation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

Northwestern University

Chicago, Illinois, 60611, United States

RECRUITING

William Beaumont Hospital

Royal Oak, Michigan, 48073, United States

RECRUITING

The Washington University

St Louis, Missouri, 63130, United States

RECRUITING

Hospital for Special Surgery

New York, New York, 10021, United States

RECRUITING

Children's Hospital of Eastern Ontario

Ottawa, Ontario, K1H 8L1, Canada

RECRUITING

Ottawa Hospital Research Institute

Ottawa, Ontario, K1H8L6, Canada

RECRUITING

CHU de Québec - Université Laval

Québec, G1J 1Z4, Canada

RECRUITING

Related Publications (1)

  • Wilkin GP, Poitras S, Clohisy J, Belzile E, Zaltz I, Grammatopoulos G, Melkus G, Rakhra K, Ramsay T, Thavorn K, Beaule PE. Periacetabular osteotomy with or without arthroscopic management in patients with hip dysplasia: study protocol for a multicenter randomized controlled trial. Trials. 2020 Aug 18;21(1):725. doi: 10.1186/s13063-020-04592-9.

MeSH Terms

Conditions

Hip Dislocation

Interventions

Polyamine Oxidase

Condition Hierarchy (Ancestors)

Joint DislocationsJoint DiseasesMusculoskeletal DiseasesWounds and InjuriesHip Injuries

Intervention Hierarchy (Ancestors)

Oxidoreductases Acting on CH-NH Group DonorsOxidoreductasesEnzymesEnzymes and Coenzymes

Study Officials

  • Geoffrey Wilkin, MD

    The Ottawa Hospital Research Institute

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Geoffrey Wilkin, MD

CONTACT

Cheryl Kreviazuk

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 15, 2018

First Posted

March 29, 2018

Study Start

April 4, 2018

Primary Completion (Estimated)

July 31, 2030

Study Completion (Estimated)

December 31, 2030

Last Updated

December 30, 2025

Record last verified: 2025-12

Locations